



ASEAN-Focused CDMO Landscape

WHY CDMO PARTNERSHIPS POWER ASEAN BIOLOGICS

Growing demand for monoclonal antibodies (mAbs), biosimilars, antibody-drug conjugates (ADCs) and next-generation biologics is driving partnerships between global manufacturing leaders and regional biopharma companies.

For ASEAN markets, CDMO partnerships unlock four core advantages that accelerate the journey from early research to commercial supply.



Faster development timelines

Supporting biotech companies from early research through clinical and commercial manufacturing.



Advanced manufacturing capabilities

Including cell culture, process development, GMP production, analytical services and scale-up expertise.



Regional manufacturing resilience

Helping Southeast Asia expand local production capacity and reduce dependence on overseas supply chains.



Technology transfer & knowledge sharing

Supporting the development of sustainable biologics ecosystems across the region.

CDMO LANDSCAPE SERVING SOUTHEAST ASIA

DIRECTORY

Leading contract development & manufacturing organisations with a Southeast Asia footprint.

Lonza
Specialized Modalities

Lonza

♦ SINGAPORE

mAbs, mammalian cell culture, biologics manufacturing, cell & gene therapy

WuXi Biologics
Global Solution Provider

WuXi Biologics

♦ SINGAPORE

End-to-end biologics CDMO, cell line development, process development, GMP manufacturing

**SAMSUNG
BIOLOGICS**

Samsung Biologics

♦ APAC

Large-scale biologics manufacturing, mAbs, biosimilars, ADC-related capabilities

**ThermoFisher
SCIENTIFIC**

Thermo Fisher Scientific

♦ SINGAPORE

Biologics development, clinical & commercial manufacturing (Patheon)

CDMO LANDSCAPE SERVING SOUTHEAST ASIA

DIRECTORY

Leading contract development & manufacturing organisations with a Southeast Asia footprint.



Boehringer Ingelheim

♦ GLOBAL / APAC

Commercial biologics, mammalian manufacturing, mAbs (BioXcellence)



AGC Biologics

♦ ASIA

Mammalian & microbial biologics, mRNA, viral vectors, plasmid DNA



Esco Aster

♦ SINGAPORE

CRDMO services, cell & gene therapy, viral vectors, GMP manufacturing



GenScript

♦ SINGAPORE

Protein engineering, gene synthesis, biologics development platforms

WHY CDMOS MATTER TO SEA'S BIOLOGICS FUTURE

The growth of ASEAN's biologics sector depends on tight collaboration across the value chain — from innovators to the healthcare systems that ultimately deliver therapies to patients.



Together, these stakeholders are building the foundation for a competitive regional biologics ecosystem.

JOIN US

CONNECT WITH BIOLOGICS LEADERS

Biologics World Southeast Asia 2026 unites global CDMOs, biotech companies, manufacturers, regulators and technology providers — including the leaders featured below — to shape the future of biologics development and manufacturing in ASEAN.

 Badarulhisam Abdul Rahman, PhD Chief Scientific Officer, Pharmaniaga Berhad, Malaysia	 Dr. Mohd Azlan bin Zaharudin Director, Malaysian Vaccine Project Office (MVPO), Ministry of Science, Technology & Innovation (MOSTI), Malaysia	 Shanti Marlina Sibuea Acting Director, Directorate of Control of Production of Drug, Narcotic, Psychotropic and Precursor, The Indonesian FDA (Badan POM), Indonesia	 Rakhmat Budi Yuwono Quality Director, Etana Technologies, Indonesia
 Andreas Gutknecht General Manager, Takeda Indonesia	 Dr. Uma Nath Tripathi Associate General Manager, Kashiv Biosciences LLC, India	 Dr. Heba Wali Vice CEO, VBC Vaccines and Biotechnology City, Egypt	 Butet Manurung Director of Quality, Jakarta Biopharmaceutical Industry (JBio), Indonesia
 Apt. Lutfhi Zarkasyi, S.Farm Director of Manufacturing, Kalbio Global Medika, Indonesia	 Meenu Batolar Global Regulatory Affairs Asia Pacific Lead, CEPI, Singapore	 Dr. Sushant Sahastrabuddhe Deputy Director General, International Vaccine Institute (IVI), South Korea	 Vipul Doshi Chief Quality and Compliance Officer, Zydus Lifescience, India
 Vinod Kumar Bura Coordinator, Immunization & Vaccine Development, WHO SEARO, India	 Indriana Permatasari Project Manager, International Vaccine Institute (IVI), Indonesia	 Dr. Soleh Ayubi Chief of Country Representative, PATH, Indonesia	 Dr. Mandeep Singh Dhingra Director and Head, R&D Programs, CEPI, USA
 Dr. Jetsumon Sattabongkot Prachumsri Director, Mahidol Vivax Research Unit, Mahidol University, Thailand	 Dr. Indra Rudiansyah Project Lead, mRNA Vaccine Programme, Bio Farma, Indonesia	 Dr. Wenshuo Zhou Senior Director R&D & CEO Scientific Assistant, Abogen Biosciences, China	 Andre Choo Deputy Executive Director, Senior Principal Scientist III, Biotherapeutics Development Group, A*STAR Bioprocessing Technology Institute, Singapore
 Dr. Karan Thakkar Vaccines Medical Director, Pfizer, Singapore	 Neni Nurainy Head of Translational Development of Life Science Product, Bio Farma, Indonesia	 Zainab Sadat General Manager, Vaccines, Southeast Asia & India MCO, Sanofi, Singapore	 M. Indra Lamora Director - Anti Infectious Department, Etana Technologies, Indonesia
 Dr. Deepak Mukherjee Country Medical Director, Roche, Indonesia	 Yagna Praveen Asst Vice President, Head of Strategic Research, Pharmaniaga, Malaysia	 Muhammad Satrio W Project Leader, New Production and QC Facility, Bio Farma, Indonesia	

KEY DISCUSSION INCLUDE

CDMO Partnerships & Technology Transfer | Scaling Biomanufacturing Capacity
Bioprocessing Innovation | Advanced Biologics Platforms
Clinical Development & Commercialisation

14-15 October 2026

 **Sheraton Grand Jakarta Gandaria City Hotel**
Jakarta, Indonesia

Join the region's leading platform
shaping Southeast Asia's next era of
biologics innovation.